Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US75886F1075
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000C734W3
REGN
Regeneron Pharmaceuticals Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Regeneron Pharmaceuticals Inc
ISIN
US75886F1075
TICKER
REGN
MIC
XNAS
REUTERS
REGN.OQ
BLOOMBERG
REGN US
Wed, 05.08.2026       Regeneron Pharmaceuticals
US75886F1075

New York, New York--(Newsfile Corp. - August 5, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Regeneron Pharmaceuticals
US75886F1075

Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”). The lawsuit alleges that Regeneron Pharmaceuticals misled investors regarding the...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Regeneron Pharmaceuticals
US75886F1075

SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma....
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Regeneron Pharmaceuticals
US75886F1075

A securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial.NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Regeneron Pharmaceuticals
US75886F1075

New York, New York--(Newsfile Corp. - August 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Regeneron Pharmaceuticals
US75886F1075

LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereun...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Regeneron Pharmaceuticals
US75886F1075

LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Sh...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Sat, 01.08.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.07.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.07.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Regeneron Pharmaceuticals
US75886F1075

New York, New York--(Newsfile Corp. - July 30, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Regeneron Pharmaceuticals
US75886F1075

Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing event accrual as potentially favorable, even as the study allegedly faced heightened risk of failing its primary endpoint.NEW YORK, July 30, 2026 /PRNewswire...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire b...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update....
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.07.2026       Regeneron Pharmaceuticals
US75886F1075

SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed dro...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.07.2026       Regeneron Pharmaceuticals
US75886F1075

Time-Sensitive: Allegations focus on Regeneron's statements about clinical differentiation in the Phase III Fianlimab-Libtayo Study and the last-minute protocol amendment used to force a trial readout.NEW YORK, July 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) of a pending se...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.07.2026       Regeneron Pharmaceuticals
US75886F1075

New York, New York--(Newsfile Corp. - July 28, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 28.07.2026       Regeneron Pharmaceuticals
US75886F1075

SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed dro...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.07.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, July 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lea...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.07.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.07.2026       Regeneron Pharmaceuticals
US75886F1075

A securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial.NEW YORK, July 28, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announce...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.07.2026       Regeneron Pharmaceuticals
US75886F1075

Lead Plaintiff Deadline: September 14, 2026SAN DIEGO, July 27, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period")....
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.07.2026       Regeneron Pharmaceuticals
US75886F1075

SAN FRANCISCO, July 27, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed dro...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sun, 26.07.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.07.2026       Regeneron Pharmaceuticals
US75886F1075

New York, New York--(Newsfile Corp. - July 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.07.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.07.2026       Regeneron Pharmaceuticals
US75886F1075

SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed dro...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.07.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FDA Otptimus-related amendments on progression-free survival analysis.NEW YORK, July 23, 2026 /PRNewswire/ -- SueWallSt alerts investors in Regeneron P...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.07.2026       Regeneron Pharmaceuticals
US75886F1075

Levi & Korsinsky, LLP alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026. Find out if you might be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky....
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.07.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.07.2026       Regeneron Pharmaceuticals
US75886F1075

San Diego, California--(Newsfile Corp. - July 23, 2026) - Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, t...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.07.2026       Regeneron Pharmaceuticals
US75886F1075

SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed dro...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.07.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the C...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, July 22, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit see...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       Regeneron Pharmaceuticals
US75886F1075

New York, New York--(Newsfile Corp. - July 22, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       Regeneron Pharmaceuticals
US75886F1075

SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed dro...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       Regeneron Pharmaceuticals
US75886F1075

SAN FRANCISCO, July 21, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed dro...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.07.2026       Regeneron Pharmaceuticals
US75886F1075

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company’s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.07.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, July 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lea...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.07.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.07.2026       Regeneron Pharmaceuticals
US75886F1075

LOS ANGELES, July 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. S...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.07.2026       Regeneron Pharmaceuticals
US75886F1075

LOS ANGELES, July 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereu...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.07.2026       Regeneron Pharmaceuticals
US75886F1075

New York, New York--(Newsfile Corp. - July 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.07.2026       Regeneron Pharmaceuticals
US75886F1075

The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REGN...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.07.2026       Regeneron Pharmaceuticals
US75886F1075

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.07.2026       Regeneron Pharmaceuticals
US75886F1075

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Com...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.07.2026       Regeneron Pharmaceuticals
US75886F1075

SAN DIEGO, July 17, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026.  Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commer...
Read more
Regeneron Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink